Evidence map›Paper›PMID 28611771›Full record

ArticleFrontiers in immunology2017

TNF Lectin-Like Domain Restores Epithelial Sodium Channel Function in Frameshift Mutants Associated with Pseudohypoaldosteronism Type 1B.

Anita Willam, Mohammed Aufy, Susan Tzotzos, Dina El-Malazi, Franziska Poser, Alina Wagner, Birgit Unterköfler, Didja Gurmani, David Martan, Shahid Muhammad Iqbal and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The Epithelial Sodium Channel-An Underestimated Drug Target.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Conformational ensemble of the TNF-derived peptide solnatide in solution.Computational and structural biotechnology journal · 2022
    Article
  8. Novel and Evolving Therapies for COVID-19 Related Pulmonary ComplicationsThe American journal of the medical sciences · 2021
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Anita WillamDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Mohammed AufyDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Susan TzotzosAPEPTICO GmbH, Vienna, Austria.
Dina El-MalaziDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Franziska PoserDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Alina WagnerDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Birgit UnterköflerDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Didja GurmaniDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
David MartanDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Shahid Muhammad IqbalDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Bernhard FischerAPEPTICO GmbH, Vienna, Austria.
Hendrik FischerAPEPTICO GmbH, Vienna, Austria.
Helmut PietschmannAPEPTICO GmbH, Vienna, Austria.
Istvan CzikoraVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Rudolf LucasVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Rosa Lemmens-GruberDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Waheed ShabbirDepartment of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
University of Vienna · ATApeptico (Austria) · ATAugusta University · US

Funding

Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritisR01DK100564 · NIDDK · AUGUSTA UNIVERSITY · PI LUCAS, RUDOLF, MADAIO, MICHAEL P · 2015 to 2017
$684k
NIDDK NIH HHS R01 DK100564Wellcome Trust
6 · The paper itself

Abstract

Previous

Indexed as

amiloride-sensitive epithelial sodium channellectin-like domain of tumor necrosis factorpseudohypoaldosteronism type 1Bsolnatide (AP301)TIP peptides

Identifiers

PMID28611771
PMCPMC5447021
OpenAlexW2617445595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.